Form 4: Vera Therapeutics CFO Sean Grant Executes Stock Option and Sells Shares

Sean Grant, CFO of Vera Therapeutics, exercised stock options and sold a significant number of shares on April 3, 2024, according to a Form 4 filing with the SEC.

Summary

• On April 3, 2024, Sean Grant, the CFO of Vera Therapeutics, exercised stock options to acquire 99,828 shares of Class A Common Stock at a price of $14.87 per share.
• Concurrently, Grant sold a total of 129,494 shares of Class A Common Stock at prices ranging from $37.70 to $40.36 per share.
• These sales were executed in multiple transactions at weighted-average prices.
• The transactions also involved sales of shares held in Roth IRA, UTMA accounts, IRA, Spouse's IRA, and a Trust.
• Following these transactions, Grant directly owns 66,337 shares and indirectly owns 22,595 shares through various accounts.
• Grant also holds options for 80,172 shares of Class A Common Stock.

Sentiment

Score: 5

Explanation: The document is a standard SEC filing detailing stock transactions by a company executive. It doesn't inherently convey positive or negative sentiment, but the market may interpret the sales as a lack of confidence or a personal financial decision.

Industry Context

Form 4 filings are standard disclosures required by the SEC to provide transparency regarding insider transactions in publicly traded companies, allowing investors to monitor the actions of company executives and directors.

Stakeholder Impact

• Shareholders may react to the insider selling activity, potentially influencing the stock price.
• The transactions do not directly impact employees, customers, suppliers, or creditors.

Key Dates